Document:

EX-10.61

 EXHIBIT 10.61 

SERVICES AGREEMENT 
 BY
AND BETWEEN 
 CORD:USE Cord Blood Bank, Inc. AND DUKE UNIVERSITY 

THIS SERVICES AGREEMENT (“Agreement”) is entered into as of July 28, 2017 (“Effective Date”), by and between
CORD:USE Cord Blood Bank, Inc., a Florida corporation (“CORD:USE”) and Duke University through its School of Medicine (“Duke”) (each a “Party” and collectively the “Parties”). 

RECITALS 
 WHEREAS, Duke
is a North Carolina nonprofit corporation exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code of 1986, as amended and operates the Carolinas Cord Blood Bank (“Duke Program”) out of its facilities
in Durham, North Carolina, among other activities; 
 WHEREAS, CORD:USE provides cord blood services to families and to the public through
its CORD:USE Family Bank and CORD:USE Public Bank, respectively. CORD:USE Public Bank is specifically focused upon establishing and maintaining a public cord blood bank for the storage and maintenance of cord blood stem cells which will be available
for research and transplantation in the treatment of various diseases (the “CORD:USE Public Bank”); 
 WHEREAS, CORD:USE
has since 2005 utilized the Duke facilities, personnel, services and infrastructure of the Duke Program to process, type, test, preserve, maintain, register and distribute cord blood publicly donated and obtained by or through CORD:USE, which as
part of the CORD:USE Public Bank (“CORD:USE Program”); 
 WHEREAS, CORD:USE fell into arrears on its payments, but desires
to continue accessing the Duke infrastructure; 
 WHEREAS, Duke and CORD:USE desire to enter into a new agreement that will allow for
repayment of the arrearage and govern the on-going provisions of services to the CORD:USE public banking operations; and 

NOW, THEREFORE, the Parties hereby enter into this Agreement to provide for the operation of the CORD:USE Program at Duke as part of the
CORD:USE Public Bank. 

  
 [Page 1
of 25] 

 AGREEMENT 

In consideration of the foregoing, the mutual promises contained in this Agreement, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties agree to be bound as follows: 
 1.    DEFINITIONS 

The following terms used in this Agreement (including the Schedules), shall have the meanings ascribed to them in this
Section 1. 
 1.1    “Accrediting or Licensing Agency” means any applicable
accrediting, regulating or licensing agencies or boards, including, but not limited to the American Association of Blood Banks, the U.S. Food and Drug Administration, the Joint Commission on Accreditation of Healthcare Organizations and the
Foundation for the Accreditation of Cellular Therapy, the National Marrow Donor Program, and the U.S. Health Resources and Services Administration. 

1.2    “Affiliate” means, as to any Party to this Agreement or any other Person, any Person that, directly or
indirectly, controls, is controlled by, or is under common control with such Person. For purposes of this definition, the term “control” or its derivations, as used with respect to any Person, means the possession, directly or indirectly,
of the power to direct or cause the direction of the management or policies of such Person, whether through ownership of voting securities, by agreement, or otherwise. 

1.3    “Agreement” means this Services Agreement. 

1.4    “Change of Control” means, with respect to a Person (the “Subject Person”), (a) the sale of all
or substantially all of the assets of the Subject Person to another Person, (b) a merger, acquisition or other transaction in which the Subject Person is the surviving corporation that results in any Person (other than Persons who are holders
of fifty-one percent (51%) or more of the stock of the Subject Person at the time the transaction is approved by the shareholders of the Subject Person and other than any Affiliate of the Subject Person)
acquiring beneficial ownership of fifty-one percent (51%) or more of the combined voting power of all classes of stock, or fifty-one percent (51%) of the voting control,
of the Subject Person, or (c) a merger, consolidation or reorganization of the Subject Person with one or more other Persons where the Subject Person is not the surviving entity and the subject transaction results in a change of beneficial
ownership of the combined voting power of all classes of stock of the Subject Person as described in the preceding clause (b). 

1.5    “Confidential Information” means all proprietary and non-public
information and data that concern the business, technology, systems, finances, personnel, operations, or other assets and activities of a Person, but does not include personally-identifiable patient data, but does include compilations or databases
containing aggregate de-identified patient data. 
 1.6    “Environmental
Laws” means any federal, state, local or foreign law, rule or regulation relating to or regulating health, safety, pollution, handling and disposal of hazardous materials or waste or the protection of the environment. 

  
 [Page 2
of 25] 

 1.7    “Governmental Entity” means any domestic government,
political subdivision, or any governmental agency, bureau, board, commission, department or regulatory agency, whether federal, state or local. 

1.8    “Hospital Rules and Regulations” means the bylaws, rules, credentialing policies, regulations, and other
policies and standards of Duke Hospital and of each Participating Hospital and their respective medical staffs. 

1.9    “Intellectual Property” means copyrights, patents (and patent applications), trade secrets, trademarks,
and service marks (including software, source codes, data, original works of authorship and other proprietary information). 
 1.10
“Law” means any constitutional provision, statute, law, rule, regulation, license, permit, or legally binding ruling of any Governmental Entity. 

2.    RIGHTS AND OBLIGATIONS OF DUKE 

2.1    Duke Services 

Duke shall continue to serve as the contract manufacturer for the CORD:USE public cord blood bank and, as such, provide or arrange for the
provision of services as set forth in more detail on Schedule 2.1 (“Duke Services”) in accordance with the terms of this Agreement. In addition, Duke shall train, and provide ongoing training to CORD:USE personnel as set forth in
Section 3.2. Subject to the capacity limits identified in Section 2.8, Duke shall receive cord blood units collected by CORD:USE staff in the Carolinas Cord Blood Bank at Duke within 2 days of
collection, qualify the shipping conditions, packaging and labeling of the unit, and count the number of total nucleated cells present in the cord blood unit to determine whether the unit contains sufficient cells for banking. If the unit meets
criteria, it will be processed by the Duke Carolinas Cord Blood Bank Processing Laboratory Staff with volume reduction, red blood cell depletion, cryoprotection with DMSO or other cryoprotectant, and frozen via controlled rate freezing under liquid
nitrogen for long-term storage. 
 All processed units will be tested for nucleated cell counts, viability, CD34 count, T-cell count, clonal hematopoietic colony forming units, sterility, and HLA typing. Maternal blood drawn on behalf of CORD:USE and shipped with the collected cord blood unit, will be tested for infectious disease
markers in a CLIA approved lab for donor screening testing as required by HRSA, FDA, AABB and FACT regulations. CORD:USE will enter all information about the birth, medical history and testing of the unit and mother into the web-based computer system employed by the Carolinas Cord Blood Bank at Duke. 
 A separate numbering
system will allow for distinction and tracking of the CORD:USE inventory. When a CORD:USE cord blood unit is selected by a transplant center for possible transplantation, Duke shall provide the relevant HLA testing laboratory with a sample from the
unit for confirmatory typing. When a unit is requested for transplantation, Duke shall ship the unit to the transplant center in a validated dry shipper with data logger. Notwithstanding the foregoing and any other provisions of this Agreement,
CORD:USE and Duke agree that the Duke Program, because of the status of Duke as a nonprofit and tax-exempt educational, health care, and research institution, will, in the event of a conflict, always take
precedence over the CORD:USE Program with respect to the dedication of Duke resources. The Parties further agree that the CORD:USE Program shall not be allowed to compromise, in any way, the Duke Program. 

  
 [Page 3
of 25] 

 2.2    Performance Standards 

Duke shall provide the Duke Services with the appropriate level and standard of care consistent with Duke’s reputation as a first-rate
academic medical facility and in no event at a level less than provided under the Duke Program, and Duke shall require that each Duke physician and any other professional or non-professional employee or
independent contractor of Duke or its Affiliates who performs or supports the performance of the Duke Services (collectively, “Duke Personnel”) (i) devote his or her best efforts to, and use his or her education, experience, skills,
and professional energy in, performing the Duke Services; and (ii) comply with the applicable terms of this Agreement, all applicable Laws, Hospital Rules and Regulations, CORD:USE Protocols and criteria of Accrediting or Licensing Agencies.

 2.3    Duke Personnel 

All Duke Personnel shall be employees or independent contractors of Duke or a Duke Affiliate. Duke shall ensure that Duke and its Affiliates
shall be solely responsible for any and all salaries, other compensation, employer’s payroll taxes, workers’ compensation coverage, and other fringe benefits to which Duke Personnel may be entitled as employees or contractors of Duke or a
Duke Affiliate. Duke shall ensure that all Duke Personnel are appropriately trained, qualified, and licensed to provide the Duke Services to the CORD:USE Program. The selection, retention, and termination of Duke Personnel shall be the sole
responsibility of Duke; provided, however, that in the event CORD:USE is not reasonably satisfied with the performance of any Duke Personnel, Duke shall promptly investigate the matter and cooperate with CORD:USE in determining a reasonable
course of action to address CORD:USE concerns subject to all applicable Duke University Human Resources policies. Any costs for the personnel incurred pursuant to this Section 2.3 in providing the Duke Services shall be
included in the Banking Services Fee described in Section 3.6 below. 
 2.4    Licenses;
Accreditations; Duke Policies; CORD:USE Protocols 
 In its provision of the Duke Services, Duke will utilize its current licenses and
accreditations to provide its services for the CORD:USE Program, and Duke will not violate any permit, operating license or governmental approval in connections with the CORD:USE Program or otherwise so long as any applicable restrictions that are
not generally applicable and known to providers in the community have been disclosed to Duke in sufficient time for Duke to ensure compliance. Duke agrees to abide by the applicable standards of the American Association of Blood Banks, the National
Marrow Donor Program, the U.S. Health Resources and Services Administration, the Foundation for Accreditation of Cellular Therapy, the U.S. Food and Drug Administration, the State of North Carolina, and any other organizations or entities agreed to
by the Parties. Duke further agrees to take all reasonable actions to cause CORD:USE Program to become accredited by and maintain accreditation with the Foundation for Accreditation of Cellular Therapies (FACT) as available. Duke agrees to notify
CORD:USE in writing within five (5) days after any such accreditation is denied or revoked or Duke is notified that the CORD:USE Program has failed to meet a standard or accreditation requirement. 

  
 [Page 4
of 25] 

 2.5    OSHA and HIV compliance 

Consistent with law and normal practice and as part of the Duke Services, Duke shall make available the hepatitis B vaccine and vaccination
services for all Duke Personnel associated with the CORD:USE Program with the potential for occupational exposure to blood borne pathogens. Duke shall submit documentation of the vaccination or a copy of the declination form if any Duke Personnel
chooses not to be vaccinated. Duke also shall provide training to all Duke Personnel prior to assignment to the CORD:USE Program that includes explanation of the OSHA blood borne pathogen standards, general discussion on blood borne diseases and
their transmission, exposure control plan, engineering and work practice controls, personal protective equipment, hepatitis B vaccine, response to emergencies involving blood, how to handle exposure incidents and the post-exposure evaluation and follow-up program. 
 2.6    Patient Medical Records; Consent 

CORD:USE shall obtain and maintain IRB approvals as indicated and prepare and obtain consent forms for all donors relating to the donation of
umbilical cord blood units to the CORD:USE Cord Blood Bank at all CORD:USE collection sites. CORD:USE also shall obtain all consents, authorizations and permissions from cord blood donors at sites where CORD:USE is performing collection of medical
history information for donor screening, collection of maternal blood samples for infectious disease testing and collection of cord blood units that are necessary and required by applicable Law and regulations to enable CORD:USE to disclose to Duke,
and for Duke to have access to and use and disclose in the course of its activities for all purposes reasonable necessary to the operation of the CORD:USE Program, including, but not limited to, for research (including informatics) and
transplantation purposes, all necessary and appropriate identifiable health information about the mother and child from who cord blood is obtained and sent to Duke pursuant to this Agreement. CORD:USE agrees that, to the extent consistent with
applicable Law and the consents, authorizations and permissions CORD:USE obtained, CORD:USE will disclose to Duke personnel designated by the Medical Director such identifiable health information and give those designated Duke Personnel access to
such information maintained by CORD:USE. 
 Duke and CORD:USE will keep, treat and maintain all identifiable health information they receive
or have access to under this Agreement in compliance with all Applicable Laws, including but not limited to the privacy and security regulations promulgated under the Health Insurance Portability and Accountability Act. 

2.7    CORD:USE Program Medical Director 

As part of the Duke Services, Duke shall provide a physician employed by Duke to serve as Medical Director of the CORD:USE Program and to
report to the CORD:USE Medical Director for purposes of performing Duke’s Medical Director obligations under this Agreement. Duke shall cause the Medical Director to supervise, in consultation with CORD:USE, the operations of the CORD:USE
Program and the delivery of the Duke Services, in accordance with the terms of this Agreement (“Medical Director”). The current Medical Director is Dr. Joanne Kurtzberg. Should Dr. Kurtzberg leave her position as Medical
Director for any reason during the Term, Duke shall provide another physician approved in advance by CORD:USE to fill that role. If at any time 

  
 [Page 5
of 25] 

 CORD:USE is not reasonably satisfied with the performance of the Medical Director, Duke shall promptly
address CORD:USE’ concerns. If the Parties are unable to agree on a course of action, the matter shall be addressed and resolved in accordance with Section 13.1. As part of the Duke Services and as set forth in
Section 10, Duke shall provide or arrange for the provision of professional liability insurance that covers the Medical Director’s activities related to the CORD:USE Program and nothing in this
Section 2.7 or elsewhere in this Agreement shall be interpreted or construed to mean that CORD:USE is responsible for extending any of its liability insurance policies, individually or collectively, to cover the Medical
Director. 
 2.8    CORD:USE Program Facilities 

Throughout the Term and as part of the Duke Services, Duke shall use the Duke Program space and facilities described on Schedule 2.8 for
activities of the CORD:USE Program and the delivery of the Duke Services (“CORD:USE Program Facilities”). All CORD:USE Program Facilities shall remain assets solely of Duke, and shall continue to be used by Duke in connection
with the Duke Program. As part of the Duke Services, Duke shall maintain, insure and improve the CORD:USE Program Facilities at a level consistent with its provision of insurance and normal operations and maintenance services to those facilities
under the Duke Program and consistent with its provision of insurance and services to other Duke Hospital facilities. Duke shall be responsible for obtaining and maintaining all material permits, licenses and authorizations under, and shall comply
in all material respects with, all Environmental Laws with respect to the CORD:USE Program Facilities. Duke shall be the generator at the CORD:USE Program Facilities of all dangerous, hazardous or toxic waste or materials and shall handle all such
waste or materials in compliance with Law and Hospital Rules and Regulations. Should Duke need to relocate the CORD:USE Program during the Term, Duke shall give CORD:USE at least ninety (90) days advance written notice and shall provide
replacement facilities at least comparable to the CORD:USE Program Facilities in size, quality location and services and shall pay all costs of relocation of the CORD:USE Program. Duke shall give good faith consideration to making additional space
contiguous to or reasonably nearby the CORD:USE Program facilities available in a timely manner for CORD:USE Program expansion needs once the banked number of cord blood units for the CORD:USE Program exceeds twenty thousand (20,000) units (e.g.
space needed to house new staff or equipment such as new freezers); provided, however, that nothing in this Section 2.8 or elsewhere in this Agreement shall be interpreted to mean that Duke will be obligated to construct,
lease, acquire or otherwise obtain or provide additional facilities, equipment or space for any expansion of the CORD:USE Program beyond the capacity of twenty thousand (20,000) banked units. In the event and to the extent that relocation and/or new
space is needed for the expansion of the CORD:USE Program and is undertaken by Duke, the expenses directly related to the new space, including renovation, moving and increased ongoing CORD:USE Program operations costs, will be paid by CORD:USE. 

2.9    CORD:USE Program Revenues 

Duke shall provide to CORD:USE on a monthly basis on or before the tenth (10th) day of each month a detailed, complete and accurate report of
all cord blood units banked and/or distributed by the CORD:USE Program during the previous month. CORD:USE shall have sole responsibility to bill or arrange for billing related to the distribution of CORD:USE units for clinical use and to collect
payments from hospitals, including Duke Hospital, Participating 

  
 [Page 6
of 25] 

 
Hospitals, and other purchasers of the cord blood units distributed by the CORD:USE Program during the Term. Duke shall have no claim to or interest in any revenues received by CORD:USE for the
cord blood units distributed by the CORD:USE Program during the Term. 
 2.10 Duke Program Contracts 

As part of the Duke Services, Duke shall maintain in full force and effect, for the benefit of the CORD:USE Program, Duke’s contracts with
the laboratory(s) for infectious disease testing, with a qualified HLA typing laboratory; and with a vendor for computer and database search support, and with the National Marrow Donor Program. Payments required of Duke under such contracts are
included in the Services Fee. Subject to the foregoing, Duke may arrange for the provision of any of the Duke Services by a third party subject to the advance written approval by CORD:USE of the third party, which shall not be unreasonably withheld.

 2.11 Duke Inventory 

Cord blood units collected by the Duke program prior to, during, and after the effective date shall not be included in the CORD:USE Program,
but shall be distributed by Duke separately per Duke’s agreement with the National Marrow Donor Program. Any expenses associated with the collection, storage or distribution of these units that are not CORD:USE Program units shall not be
included in the CORD:USE Program Services Fee or otherwise paid by CORD:USE. Under no circumstances shall CORD:USE be liable to Duke or HRSA or to any of their respective Affiliates, customers, contractors or suppliers or any other Person for these
cord blood units that are not CORD:USE Program units or for any liability of any kind or description arising from, attributable to, or connected with them, or their collection, processing, testing, storage, handling, distribution and/or use. 

2.12 CORD:USE Program Inventory 

NMDP shall notify Duke when and where CORD:USE Program cord blood units are to be distributed and Duke shall distribute those units in
accordance with this Agreement. CORD:USE Program units shall be available to Duke at market value (i.e., the same price charged third parties) for its use in transplantation therapy. For all units collected but not banked by the CORD:USE Program in
accordance with CORD:USE Protocols developed in accordance with Section 2.12, Duke shall have the right to use those excluded units for its own research purposes, including for research projects in which it participates
jointly with third parties. Excess excluded units not used by Duke in accordance with this Section 2.12 shall be made available by Duke to CORD:USE for its use or distribution for research. Notwithstanding any other
provision of this Agreement, Duke shall not sell any excluded units to any third parties or use these units for other than research purposes without the written approval of CORD:USE. 

2.13 Duke IRB 
 As part of
the Duke Services, Duke shall ensure that any and all CORD:USE Program activities or protocols that require Duke IRB review and/or approval will be reviewed by the Duke IRB in the normal course. 

  
 [Page 7
of 25] 

 3.    CORD:USE RIGHTS AND RESPONSIBILITIES 

3.1    Compliance 

CORD:USE agrees to: (i) comply with all applicable Laws relating to its receipt of the Duke Services and to its CORD:USE Program
operations generally; (ii) provide Duke all information reasonably necessary for Duke to carry out its obligations under this Agreement; (iii) cooperate in good faith with Duke in order to support. Duke’s effort to carry out those
obligations; and (iv) satisfy and perform all of its obligations under this Agreement. CORD:USE shall comply with its obligations under this Agreement in good faith, with reasonable diligence, and in compliance with all applicable Laws and the
prevailing standard of care for programs similar to the CORD:USE Program. CORD:USE shall (a) maintain all licenses and certifications necessary and required for its operation of the CORD:USE Program (subject to Duke’s compliance with its
responsibilities as set forth in this Section 3.1 and otherwise in the Agreement), and (b) require that all CORD:USE Personnel (as defined in Section 3.2) associated with the CORD:USE Program
perform their duties in accordance with the requirements of this Agreement and all applicable Laws. 

3.2    CORD:USE Personnel 

CORD:USE shall provide, or otherwise arrange for the provision of, staff to 1) respond to Duke’s reasonable inquiries or requests for
direction, guidance and/or approvals sufficient to enable Duke to deliver the Duke Services in accordance with this Agreement; and 2) perform all collection of cord blood units at Participating Hospitals for the CORD:USE Blood Bank as part of the
CORD:USE Program under this Agreement, except for collection performed by Duke Personnel under Section 2.3 of this Agreement. All such personnel (“CORD:USE Personnel”) shall be employees or independent
contractors of CORD:USE, and CORD:USE shall be solely responsible for any and all salaries, other compensation, employer’s payroll taxes, workers’ compensation coverage, and other fringe benefits to which CORD:USE Personnel may be
entitled as employees or contractors of CORD:USE. The selection, retention, and termination of CORD:USE Personnel shall be the sole responsibility of CORD:USE; provided, however, that in the event Duke is not reasonably satisfied with the
performance of any CORD:USE Personnel as it impacts the performance of the CORD:USE Program, CORD:USE shall promptly investigate the matter and cooperate with Duke in determining a reasonable course of action to address Duke’s concerns. Under
no circumstances shall Duke Personnel, including• the Medical Director, be interpreted to be, or construed to be, CORD:USE Personnel. 

3.3    Development and Adoption of CORD:USE Protocols 

CORD:USE shall mirror CCBB’s Standard Operating Procedures (SOPs) for screening of cord blood maternal donors, supply and facility
maintenance, cord blood collection, and training of cord blood recruiters, educators and collectors. CORD:USE will use the document management system in use at CCBB for training and SOP management to ensure CORD:USE uses the same critical supplies
and documents, and applies the same SOP version as the CCBB. 

  
 [Page 8
of 25] 

 3.4    CORD:USE Program Equipment 

CORD:USE initially provided a Thermo Genesis BioArchive Freezer (“BioArchive” — HD9119) plus Service Contract, which Duke
installed in the CORD:USE Program Facilities at CORD:USE’ expense. Subsequently, CORD:USE provided a second BioArchive (HD9161) plus Service Contract which was installed at Duke. Duke shall provide electricity and liquid nitrogen necessary to
operate the two BioArchives without cost to CORD:USE. Any new equipment that CORD:USE desires to be acquired, installed and maintained for the operation of the CORD:USE Program (“CORD:USE Program Equipment”) shall be paid for by
CORD:USE. Any additional BioArchive units which become necessary for the CORD:USE Program shall be provided by CORD:USE at its sole expense and shall be maintained and operated by Duke including provision of electricity and liquid nitrogen. If,
during the Term, Duke feels an item is reasonably necessary for the responsible operation of the CORD:USE Program but CORD:USE disagrees, Duke shall have the right to purchase the item at its cost and submit the issue of whether the item is
reasonably required thus will be included in the CORD:USE Program Equipment to the dispute resolution procedure set forth in Section 13.1. Until and unless the item in dispute is determined to be CORD:USE Program Equipment
either by agreement of the Parties or by final decision of an arbitrator, the disputed item will remain owned by Duke and Duke’s responsibilities with respect to the item will be the same as if the item were included in Duke Program Equipment.
CORD:USE will cover all costs of maintenance contracts for the CORD:USE Program Equipment. Duke shall, at the expense of CORD:USE maintain in good operating order, insure and repair promptly when appropriate, the CORD:USE Program Equipment
throughout the Term. Upon termination of this Agreement, CORD:USE shall be the sole and exclusive owner of the CORD:USE Program Equipment, including all alterations, additions, improvements, repairs and replacements to that equipment, and, Duke
shall have no right, title or interest in or to the CORD:USE Program Equipment. Duke shall take all actions necessary to keep the CORD:USE Program Equipment free of all liens, claims, security interests, and other encumbrances of any kind (other
than purchase money liens). Duke shall be responsible throughout the Term for maintaining compliance of the CORD:USE Program Equipment with all applicable Laws. 

3.5    Medical Records 

Subject to Section 2.6, CORD:USE and Duke, respectively, will keep, treat and maintain all identifiable health
information it receives or has access to under this Agreement in compliance with all applicable Laws and will not disclose it to third parties except to the extent necessary for unit selection or transplantation by transplanting personnel consistent
with the consents and authorizations obtained from the cord blood donors by Duke or CORD:USE, as applicable, as set forth in Section 2.6. 

3.6    Fees and Payments 

3.6.1 CORD:USE Program Fee 

CORD:USE will pay Duke as compensation for the Duke Services over the Term of this Agreement a fee for each CBU cryopreserved for CORD:USE
(“Banking Services Fee”), which includes all direct and indirect costs of providing the Duke Services. The Banking Services Fee will be calculated as follows: 

  
 [Page 9
of 25] 

 (i)    Beginning July 1, 2017, a monthly flat fee of $40,000 will
be paid by CORD:USE to the CCBB by the 10th day of the month. The fee for July 2017 is due and payable upon contract execution. This flat fee covers the costs associated with processing and banking up to 12 CBUs that are cryopreserved with a final
disposition for CORD:USE each month. This fee applies regardless of the collection date of the CBU. The flat fee of $40,000 is due in full by the 10th day of each month, regardless of whether 0-12 cord blood
units are cryopreserved with a final disposition in a given month. 
 (ii)    Every six months, on July 1 and
January 1, Duke will reconcile the CBUs that have been cryopreserved with a final disposition (CFO) for CORD:USE. An invoice with payment required within thirty (30) days of receipt will be generated using the following fee schedule for
CBUS cryopreserved over 60: 
 a)     Each of the next 61-300 CFO CBUs/6 months
will be charged at $4,000 per CBU; 
 b)     Any CFO CBUs over 300/6 months will be charged at $3,000 per CBU; 

The Banking Services Fee will be paid when the cryopreserved CBUs’ disposition is finalized [CFO] (listed or disqualified following
cryopreservation for absence of maternal blood samples, positive for infectious disease marker, positive sterility screen, medical history exclusion or other unanticipated information disqualifying the cord blood unit post cryopreservation). The
baseline criteria for which CORD:USE CBUs will be cryopreserved will follow the criteria used for cryopreservation of CCBB units, which currently is as follows: (1) collection volume of >60mls for minority units, 80 mls for Caucasian units, (2) pre-processing cell count of lx10e9 cells, and (3) post-processing viability of >90%. This criteria will be subject to change if CCBB’s criteria changes in the future. This Banking Services Fee
is subject to an annual three and a half percent (3.5%) increase each year effective as of February 1, of the given year. In addition, if Duke is subject to significant (more than 15%) cost increases due to regulatory or operational changes the
parties agree to negotiate a revision to the Banking Services Fee based on actual costs. 
 The Banking Services Fee paid for cryopreserved
CBUs shall include all of Duke’s costs, including personnel, services and materials for all cord blood units sent to Duke from CORD:USE. Any additional requests for Duke services, i.e. BLA submission, regulatory responses or inspection costs,
are not included in this Agreement and will be negotiated and reflected in separate agreement. CORD:USE will be responsible for all collection of CBUs sent by CORD:USE to Duke for processing and cryopreservation. CORD:USE will also be responsible to
procure collection supplies pursuant to CCBB specifications, including collection bags, maternal blood tubes, ISBTD and demand-128 labels. CORD:USE is responsible for maintaining vendor services agreements on
its two existing BioArchive freezers, and will be responsible for purchase and vendor service agreements on any future BioArchive freezers needed to cryopreserve the CORD:USE CBUs. CORD:USE will be responsible for securing, maintaining access to and
utilizing MasterControl document management system, for training and SOP management to enable seamless document control between CORD:USE and Duke. 

  
 [Page 10
of 25] 

 3.6.2 CORD:USE ARREARAGE 

CORD:USE shall pay the past due amount of Two Hundred Ninety Thousand and Two Hundred and Twelve Dollars ($290,212) owed to Duke on the
following schedule: 
 $30,000.00 to be received on or before September 30, 2017 

$30,000.00 to be received on or before October 31, 2017 

$35,000.00 to be received on or before November 30, 2017 

$35,000.00 to be received on or before December 31, 2017 

$35,000.00 to be received on or before January 31, 2018 

$35,000.00 to be received on or before February 28, 2018 

$35,000.00 to be received on or before March 31, 2018 $ 

35,000.00 to be received on or before April 30, 2018 

$20,212.00 to be received on or before May 30, 2018 

3.6.3 CORD:USE RESEARCH UNITS 

CORD:USE hereby consents to Duke’s use of ten (10) CORD:USE units for research. Five (5) of which have already been selected and
utilized. Further, and in the spirit of cooperation between the parties, Duke agrees to notify CORD:USE of any units utilized and the nature of the research purposes for which these units are being deployed. 

3.7 CORD:USE IRB 

CORD:USE Program activities, specifically including CORD:USE cord blood collection activities, shall require CORD:USE IRB approval and
CORD:USE shall provide for and facilitate the review of the CORD:USE Program by its Institutional Review Board. 
 3.8 TAXES 

All taxes of any type imposed on a Party and associated with the activities of the CORD:USE Program, including associated with any service or
other activity undertaken in connection with this Agreement, shall be paid by CORD:USE. 
 3.9 TRAINING 

In accordance with Section 2.1 DUKE may train CORD:USE personnel referred to DUKE. CORD:USE must request training
dates at least four weeks prior to desired training dates. DUKE will make every effort to accommodate the requested dates. 
 For the basic
introduction training held at DUKE’s Rex Hospital collection site, DUKE can train a maximum of four people per training session. There must be a minimum of 1 week between training sessions. All seats in any given class may not be available to
CORD:USE, as they may be required for other DUKE trainees. At least fourteen (14) days prior to the beginning of agreed upon training classes, CORD:USE shall provide DUKE with the name, position title, and collection site of each trainee. At
the same time, CORD:USE shall also provide completed employee health forms to Rex Hospital Employee Health. If these forms are not provided at least 14 days ahead of scheduled training begin date, the trainee will not be permitted to participate in

  
 [Page 11
of 25] 

 
the training session. Upon arriving for training, trainees must provide the instructor their completed prerequisite forms. Prerequisites including shadowing specific activities at their
collection site prior to arriving for training, reading Dr. Moise’s article “What to tell patients about cord blood banking”, and viewing the “Gift of Hope” and “Caroline’s Miracle” videos or comparable
updated materials created by CORD:USE or DUKE. Trainees who have not completed these requirements will not be allowed to participate in the training session. 

The cost-based charge for each person completing the basic introduction training class is $640 (inclusive of indirects) and will be invoiced
on a monthly basis. Charges for all other types of training will be estimated at the time of the training request and invoiced at the actual cost in the monthly invoice. 

3.10 ADDITION OF PARTICIPATING HOSPITALS 

CORD:USE shall provide DUKE with written notice of the addition of a Participating Hospital at which CORD:USE will be collecting cord blood
units which will be subject to the Duke Services under this Agreement. Such notice shall be provided to Duke at least 90 days in advance of the commencement of cord blood collection activities by CORD:USE to permit appropriate planning to be done
with respect to training and preparation for performance of the Duke Services. 
 4.    ACCESS TO RECORDS AND DATA 

4.1    Commitment to Share Materials 

The Parties agree that during the Term each shall make available to the other such products, forms, systems, data, reports, manuals, financial
statements, and related materials (“Materials”) as are reasonably necessary for each Party to perform its obligations set forth in this Agreement and to audit compliance of the other Party with those obligations. Each Party’s
provision of the Materials shall be subject to the proprietary rights of that Party or any third party in those Materials. 

4.2    Government Access 

If applicable, the Parties shall comply with the provisions of Section 1861(v)(1)(I) of the Social Security Act and shall make available,
upon written request of the Comptroller General of the United States or the Secretary of the United States Department of Health and Human Services or any of their duly authorized representatives, any books, documents and records that are necessary
to verify the nature and extent of the costs incurred by either Party under this Agreement. In addition, each Party shall cooperate with the other Party and provide reasonable access to books and records pertaining to this Agreement and the
performance of its obligations to the extent reasonably necessary for compliance with any governmental agency review or audit of the other Party. This Section 4.2 shall survive termination or expiration of this Agreement.

 4.3    Cooperation in Connection with Audits. 

Each Party will cooperate with the other Party in any mandated or required external audits concerning the CORD:USE Program by Governmental
Entities or CORD:USE Program contractors. This cooperation which include notifying the other Party within one week after receipt 

  
 [Page 12
of 25] 

 
of any such audit notice and making available to the other Party books and records related to the CORD:USE Program’s operations. Duke’s participation in any audits or inspections of
CORD:USE Program’s BLA application or license will require a separate fee to be negotiated in a separate agreement. 

5.    RESEARCH 
 With
respect to the CORD:USE Program, the Parties intend to work together to seek out opportunities for joint research projects. Notwithstanding the foregoing, the Parties agree that each of them and/or their Affiliates will be free to pursue pre-clinical research, clinical research and/or drug trial funding with respect to cord blood or CORD:USE Program activities, and each Party will control the funding and payment of expenses (including data costs)
for any pre-clinical research, clinical research or drug trial funding it obtains or for which it contracts on its own. 

6.    INTELLECTUAL PROPERTY RIGHTS 

6.1    Ownership of Intellectual Property 

6.1.1 Reservation of Rights 

Other than as specifically provided for in this Agreement, this Agreement does not and is not intended to transfer to either Party any rights
in any technology or Intellectual Property. 
 6.1.2 Pre-existing Intellectual Property 

Duke and CORD:USE shall each retain its interests in all Intellectual Property that each owned prior to the Effective Date of this Agreement.
Duke and CORD:USE each agree to reproduce, and agree not to remove or obscure, proprietary rights legends (such as copyright notices, among others) that are displayed on any material, regardless of form or format, provided in connection with this
Agreement. 
 6.1.3 Intellectual Property Produced During Term 

Any invention, adaptation, modification, or change primarily relating to, dependent upon or incorporating the Intellectual Property or
Confidential Information of either Party (“Improvement”) made by Duke Personnel associated with the CORD:USE Program, made jointly by these Duke Personnel and CORD:USE Personnel, or made solely by CORD:USE Personnel shall be the
sole property of the Party owning the Intellectual Property to which the Improvement is made and that Party shall have the right to apply for copyrights, patents (including utility and design patents), or other protection for Intellectual Property
rights in such Improvement anywhere in the world under its own name and at its own expense. Each Party shall promptly notify the other party of any Improvement made by the notifying Party to the Intellectual Property of the other Party. Each Party
agrees to take all actions and execute all documents, including assignments to the other Party, to effectuate the other Party’s ownership of any Improvement. Utilizing, combining, or further processing output data from Intellectual Property
shall not be considered an Improvement. Any technology or Intellectual Property that is not an Improvement created by either Party during the Term in performance of its obligations under this Agreement shall be disclosed by the Party creating the
Intellectual Property to the other Party and the Parties 

  
 [Page 13
of 25] 

 
will negotiate ownership terms based upon inventorship as determined by US patent law, or if not patentable that fairly reflect each Party’s contribution and involvement. For the avoidance
of doubt, databases developed by Duke at its own cost (i.e., expenses are not part of the Program Budget) based upon data collected by the CORD:USE Program shall be the property of Duke, and databases developed by CORD:USE based on data collected by
the CORD:USE Program shall be the property of CORD:USE. Each Party shall have full access in compliance with the terms of this Agreement and applicable law to all data collected by the CORD:USE Program for purposes of developing databases or data
products. If any technology or Intellectual Property is conceived or reduced to practice in the performance of work funded by the United States government, then the Parties will comply with this Section 6.1.3 to the extent
that it does not conflict with applicable government regulations set forth in 37 CFR 401.14. 
 6.2    Marketing; Use
of Trademarks or Service Marks 
 CORD:USE shall retain responsibility for any marketing and public relations activities related to the
CORD:USE Program. However, subject to Section 6.3, CORD:USE shall submit to Duke in advance for its approval any materials using the Duke name. Neither Party will use in advertising, publicity or otherwise, the name of any
employee or agent, any trade-name, trademark, trade device, service mark, symbol (collectively “Mark”) or any abbreviation contraction or simulation of any Mark, owned by the other Party without the prior written consent of the
other Party, which may be withheld at the sole discretion of the other Party. No Party will acquire any right or interest in any Mark of the other Party by virtue of this Agreement. Neither Party will represent, either directly or indirectly, that
any product or service of the other Party is a product or service of the representing Party or that it is made in accordance with or utilizes the information or documents of the other Party. Notwithstanding the foregoing, this Agreement will not
restrict or limit the fund raising or capital campaign efforts of either Party, except that each Party will notify the other Party in advance of any campaigns that focus specifically or substantially on the CORD:USE Program. 

6.3    Name of CORD:USE Program 

Notwithstanding Section 6.2, the CORD:USE Program will be known as “CORD:USE Cord Blood Bank at Duke” and
the Parties may use this name in describing or referencing the CORD:USE Program in ongoing activities in the normal course and in fulfilling obligations set forth in this Agreement. Any use of that name in advertising and publicity shall require the
prior written approval of Duke. 
 7.    CONFIDENTIALITY AND NON-DISCLOSURE 

7.1    Non-Disclosure 

Except as expressly provided for in this Agreement, each Party (as the “Receiving Party”) shall keep confidential, and shall cause
its controlled Affiliates and its and their officers, directors employees, agents and subcontractors (collectively, “Representatives”) to keep confidential, all Confidential Information acquired from the other Party, its Affiliates or any
of their respective Representatives (collectively, the “Disclosing Party”) (whether such information is furnished in oral or written form or whether such information is observed) in respect of the transactions 

  
 [Page 14
of 25] 

 
contemplated by this Agreement. and the Receiving Party shall not disclose to any person directly or indirectly, and shall cause its respective Affiliates and Representatives not to disclose
directly or indirectly, any Confidential Information of the Disclosing Party to anyone outside the Receiving Party, such Affiliates and their respective Representatives, provided, however, that the foregoing restrictions shall not apply to any
information disclosed hereunder to any Party if such Person can demonstrate that such Confidential Information: 

(i)    Is or hereafter becomes generally available to the trade or public other than by reason of any breach hereof; 

(ii)    Was already known to the Receiving Party or such Affiliate or Representative as shown by written records (it being
understood that Confidential Information has been shared and protected beginning with the original agreement starting in January, 2005); 

(iii)    Is disclosed to the Receiving Party or such Affiliate or Representative by a third party who has the right to
disclose such information; or 
 (iv)    Is developed independently by the Receiving Party without use of or reliance
upon information from the Disclosing Party. 
 7.2    Disclosure Required by Governmental Authority 

If required by law or order of any government authority, the Receiving Party may disclose to such authority Confidential Information to the
extent required by such order or law, provided that the Receiving Party shall have first notified the Disclosing Party of such order or law and the Disclosing Party shall have had a reasonable opportunity to oppose such disclosure or obtain a
protective order (including but not limited to “confidential treatment” pursuant to U.S. securities laws) reasonably satisfactory to the Disclosing Party to maintain the confidentiality of such data, information or materials. 

7.3    Protection of Confidential Information; Restrictions on Use, 

Each Party shall deal with Confidential Information so as to protect it from disclosure with a degree of care not less than that used by it in
dealing with its own information of like importance and intended to remain exclusively within its knowledge, and shall take reasonable steps to reduce the risk of disclosure of Confidential Information. Other than as provided in this Agreement, the
Receiving Party agrees that it shall not at any time (and shall not permit any of its Affiliates to) use any Confidential Information for any purpose whatsoever, without the prior written consent of the Disclosing Party. These obligations shall
continue for three (3) years after the termination of this Agreement. 
 7.4    Return of Confidential
Information 
 Upon termination or expiration of this Agreement, the Receiving Party shall promptly discontinue use of the Confidential
Information and any portion of that Confidential Information and promptly return all such Confidential Information in its possession to the Disclosing Party, including all copies and any compilations, analyses, studies or the like that are based on
or incorporate such Confidential Information. 

  

[Page 15 of 25] 

 8.    TERM AND RENEWAL 

The initial term of this Agreement shall commence on July 1, 2017 and continue until July 31, 2020, (“Term”) unless
this Agreement has been earlier terminated as provided in Section 9. Either party may give written notice to the other party not later than one (1) year prior to the expiration of the Term that it does not wish to
renew this Agreement, and if such notice is given then this Agreement shall expire at the end of the Term. If such notice of non-renewal is not given, then this Agreement shall automatically renew for
successive three (3) year terms (each such additional term being a “Renewal Term”), subject to termination as provided for in Section 9 below. 

9.    TERMINATION 

9.1    Termination by Duke 

Duke may terminate this Agreement under the following circumstances: 

9.1.1 If CORD:USE shall apply for or consent to the appointment of a receiver, trustee, or liquidator of all or a substantial part of its
assets, file a voluntary petition in bankruptcy or admit in writing the inability to pay its debts as they become due, make a general assignment for the benefit of creditors, file a petition or an answer seeking reorganization or arrangement with
creditors or to take advantage of any insolvency law, under which the court has either rejected or not assumed the entirety of this Agreement without modification on or before thirty (30) days after filing, or if three or more creditors of
CORD:USE file an involuntary petition under any state or federal reorganization, insolvency, arrangement, bankruptcy, or other debtor relief provision that is not dismissed within thirty (30) days of filing; 

9.1.2 If CORD:USE shall materially default in the performance of any of its material obligations under this Agreement; and 

9.1.3 If CORD:USE is conducting its cord blood unit collection activities in a manner that is inconsistent with the prevailing standard of
care, or is otherwise engaged in activities or practices that Duke reasonably believes may impede the safe and efficient operations of the CORD:USE Program under this Agreement. 

9.1.4 For convenience with ninety (90) days written notice. 

9.2    Termination by CORD:USE 

CORD:USE may terminate this Agreement under the following circumstances: 

9.2.1 If Duke shall apply for or consent to the appointment of a receiver, trustee, or liquidator of all or a substantial part of its assets,
file a voluntary petition in bankruptcy or admit in writing its inability to pay its debts as they become due, make a general assignment for the benefit of creditors, file a petition or an answer seeking reorganization or arrangement with creditors
or to take advantage of any insolvency law, under which the court has either rejected or not assumed the entirety of this Agreement without modification on or before thirty (30) days after filing, or if three or more creditors of Duke files an
involuntary petition under any state or federal reorganization, insolvency, arrangement, bankruptcy, or other debtor relief proceeding that is not dismissed within thirty (30) days after filing; 

  
 [Page 16 or 25] 

 9.2.2 If Duke Hospital is no longer licensed to operate as an acute care hospital; 

9.2.3 The loss, supervision or restriction of Duke Hospital’s right to participate in the Medicare or Medicaid programs; and 

9.2.4 If Duke and/or the Medical Director shall materially default in the performance of any of their material obligations under this
Agreement. 
 9.2.5 For convenience with ninety (90) days written notice. 

9.3    Opportunity to Cure 

Each party will have a thirty (day) right to cure a breach of this Agreement, other than a breach involving the payment of money. If a payment
due under 3.6.1 or 3.6.2 is not received when due, CORD:USE shall have a three (3) business day (Monday through Friday) period following the due date for cure. If payment is not received by the fourth day following the due date, Duke may
terminate the agreement with fifteen (15) days written notice. 
 9.4    Effect of Termination 

Upon the termination or expiration of this Agreement, each Party shall (a) promptly return to the other any books, records, or materials
that belong to such other Party, and (b) reasonably cooperate with the other Party to effectuate the orderly termination of the Agreement. If this Agreement is terminated for any reason or is not renewed at the expiration of the Term, a monthly
flat fee of $5,500 will be paid by CORD:USE to the CCBB by the 10th day of the month for storage of all CORD:USE Program Inventory and distribution of up to three (3) units per month. For each additional unit distributed, CORD:USE will pay an
additional $2,500 per unit. Distribution will be reconciled on a monthly basis. These fees are subject to an annual three and a half percent (3.5%) increase each year from the date of this Agreement and applied in full as of the date of termination
and annually thereafter. At any time following termination of this Agreement, CORD:USE may remove, in a commercially reasonable manner and at its sole cost, its CORD:USE Program Cord Blood Inventory and CORD:USE Program Equipment at which time the
distribution fees will terminate. If CCBB ceases operations, the storage and distribution of the CORD:USE Program Cord Blood Inventory also ceases and CORD:USE shall remove, at its sole cost, its Inventory and Equipment. The storage and distribution
arrangement will continue for five (5) years following termination of this Agreement, and automatically renews for additional five (5) year terms as long as the storage and distribution arrangement does not materially compromise the Duke
program. Duke must notify CORD:USE in writing with specificity, no less than 90 days prior to any automatic renewal, if Duke believes that continuation of the storage and distribution arrangement beyond the initial five (5) year period will
materially compromise the Duke program. CORD:USE and Duke will then try to find a mutually acceptable solution to the material compromise of the Duke program, prior to CU being required to remove, at its sole cost, its Equipment and Inventory, which
it may do in a commercially reasonable time and manner. Duke is responsible, at its cost, to assemble the CORD:USE Program Inventory in the CORD:USE freezers for transfer. 

  
 [Page 17 of 25] 

 CORD:USE shall be entitled to remove in a commercially reasonable manner, its CORD:USE Program Cord Blood
Inventory and CORD:USE Program Equipment. 
 9.5    Force Majeure 

Notwithstanding anything in other sections of this Agreement to the contrary, the time for performance by a Party (“Non-Performing Party”) of its obligations under this Agreement (including any cure period under Section 9.3 shall be extended for any period of delay for which performance
in the customary manner shall be prevented, hindered, or delayed by any event not within the control or caused by the fault of the Non-performing Party including, but not limited to court orders; governmental
requirements; acts or failure to act of the other Party; unknown, undisclosed or concealed conditions; strikes; lockouts; fire; explosions; theft; floods; riot; civil commotions; war; malicious mischief; earthquake; materials shortages (on
commercially reasonable terms) and/or acts of God; and/or other conditions generally constituting an event of “force majeure”: provided, however, that if any such delay or failure to perform by a Party continues for more than the
period of delay caused by the event of force majeure, the other Party shall have the right to terminate this Agreement in accordance with its terms. 

10. INSURANCE 
 10.1 CORD:USE shall
maintain the following self-insurance or insurance policies in full force and effect at all times during the Term of this Agreement: (i) Commercial General Liability insurance, including Products and Completed Operations Liability coverage and
Contractual Liability coverage, in an amount not less than $5,000,000 per occurrence/$5,000,000 annual aggregate; (ii) Professional Liability (Errors & Omissions/Medical Malpractice) insurance in an amount not less than $5,000,000 each
medical incident/$5,000,000 annual aggregate; (iii) Workers’ Compensation Insurance insuring all CORD:USE personnel who are CORD:USE employees in accordance with the statutory requirements of all states where work under this Agreement is
performed and Employers Liability insurance in an amount not less than $1,000,000 per accident/$1,000,000 per disease/$1,000,000 disease (each employee); (iv) Automobile Liability insurance including hired and
non-owned automobile liability in an amount not less than $1,000,000 per occurrence/$2,000,000 annual aggregate; (v) Property “All Risk” insurance insuring the CORD:USE Program Equipment in
accordance with Section 3.4 and (vi) Directors and Officers Liability (Errors & Omissions) insurance in an amount not less than $5,000,000 per occurrence and $5,000,000 annual aggregate for claims arising from
the activities of the CORD:USE personnel at all times and as set forth in the Agreement. With respect to self-insurance coverages, CORD:USE agrees that it will take commercially reasonable steps to ensure that it maintains at all times adequate
funds within its self-insurance program to cover claims at the levels identified above. 
 10.2 Duke shall maintain the following
self-insurance or insurance policies in full force and effect at all times during the Term of this Agreement: (i) Commercial General Liability insurance, including Products and Completed Operations Liability coverage and Contractual Liability
coverage, in an amount not less than $5,000,000 per occurrence/$5,000,000 annual aggregate; (ii) Professional Liability (Medical Malpractice) insurance applicable to any service supplied by Duke to CORD:USE under Agreement, including but not
limited to the work of the Duke Personnel, including the Medical Director, in an amount not less than $5,000,000 each medical 

  
 [Page 18
of 25] 

 
incident $5,000,000 annual aggregate; (iii) Workers’ Compensation Insurance insuring all Duke personnel who are Duke employees in accordance with the statutory requirements of all
states where work under this agreement is performed and Employers Liability insurance in an amount not less than $1,000,000 per accident/$1,000,000 per disease/$1,000,000 disease (each employee); (iv) Automobile Liability insurance including hired
and non-owned automobile liability in an amount not less than $1,000,000 per occurrence/$2,000,000 annual aggregate; (v) Property “All Risk” insurance insuring Duke’s obligations as set
forth in Section 2 and insuring all Cord Blood Units while in the care, custody, and control of Duke for their Fair Market Value as established by the current sales price of a cord blood unit at the time of loss or damage;
and (vi) Directors and Officers Liability (Errors & Omissions) insurance in an amount not less than $5,000,000 per occurrence and $5,000,000 annual aggregate for claims arising from the activities of the Duke personnel, including the
Medical Director at all times and as set forth in the Agreement. With respect to self-insurance coverages, Duke agrees that it will take commercially reasonable steps to ensure that it maintains at all times adequate funds within its self-insurance
program to cover claims at the levels identified above. 
 10.3 Each Party shall provide the other upon written request a certificate of
insurance as evidence of the self-insurance or insurance required by this Section 10 and such certificates shall provide for not less than 30 days’ notice of cancellation, termination,
non-renewal or a material change which reduces the amounts, terms or conditions of the coverage below that required in this Section 10. If replacement insurance (without any gap in
coverage) meeting the requirements of this Agreement is not obtained by the Party whose coverage is affected, then the other Party shall have the right to terminate this Agreement immediately upon notice to the other Party. 

11. INDEMNIFICATION 
 11.1
Responsibility for Own Acts 
 Except as otherwise provided in this Section 11, each Party shall be responsible
for its own acts and omissions and any and all claims, liabilities, injuries, suits, demands, and expenses of all kinds which may result or arise out of any alleged malfeasance or neglect caused or alleged to have been caused by that Party, its
employees or representatives, in the performance or omission of any act or responsibility of that Party under this Agreement. In the event that a claim is made against both Parties, it is the intent of both Parties to cooperate in the defense of
this claim. However, each Party shall have the right to take any and all actions it believes necessary to protect its interests. 
 11.2
Agreement to indemnify 
 Subject to the conditions, provisions and limitations of this Section 11, and other
applicable provisions of this Agreement, CORD:USE shall not be liable to Duke, any of Duke’s Affiliates, customers, contractors or suppliers or any other Person for, and Duke shall indemnify, defend and hold harmless CORD:USE and its Affiliates
and their respective, directors, officers, employees and agents (collectively, the “CORD:USE Indemnitees”), from and against any losses, liabilities, suits, claims, costs, expenses (including reasonable attorneys’ fees and
disbursements), interest, penalties, fines, judgments and actual or direct damages which result from bodily injury, death or property damage (collectively “Losses”) to the extent that such Losses are a result of the negligent acts
or omissions of Duke or its Affiliates and their respective directors, officers, employees, or agents in the performance of its obligations under this• Agreement, except to the extent and proportion such Losses are caused by the act or omission
of the CORD:USE Indemnitees. 

  
 [Page 19
of 25] 

 Subject to the conditions, provisions and limitations of this
Section 11, and other applicable provisions of this Agreement, Duke shall not be liable to CORD:USE, any of CORD:USE’ Affiliates, customers, contractors or suppliers or any other Person for, and CORD:USE shall
indemnify, defend and hold harmless Duke, and its directors, officers, employees and agents (collectively, the “Duke Indemnitees”), from and against any losses, liabilities, suits, claims, costs, expenses (including reasonable
attorneys’ fees and disbursements), interest, penalties, fines, judgments and actual or direct damages which result from bodily injury, death or property damage (collectively “Losses”) to the extent that such Losses are a
result of the negligent acts or omissions of CORD:USE or CORD:USE Affiliates and their respective directors, officers, employees, or agents in the performance of its obligations under this Agreement, except to the extent and proportion such Losses
are caused by the act or omission of the Duke Indemnitees. 
 11.3 Conditions to Indemnification 

The obligations and liabilities of the Parties with respect to their respective indemnities resulting from any claim, demand or other assertion
of liability by third parties (hereunder• called collectively “Demands”), shall be subject to the following terms and conditions: 
  

	 	a)	 Subject to the consent of the indemnified Party (“Indemnified Party”) (such consent not to be
unreasonably withheld or delayed), the indemnifying Party (“Indemnifying Party”) shall have the right to undertake, by counsel or representatives of its own choosing, the defense, compromise or settlement of any such Demand asserted
against the Indemnified Party, such defense, compromise or settlement to be undertaken on behalf of and for the account and risk of the Indemnifying Party. 

  

	 	b)	 In the event the Indemnifying Party shall elect not to undertake such defense by its own representatives, the
indemnifying Party shall give prompt written notice of its election to the Indemnified Party, and the Indemnified Party shall undertake the defense, compromise or settlement thereof by counsel or other representatives designated by it whom the
Indemnifying Party determines in writing to be satisfactory for such purposes. The consent of the Indemnifying Party to the Indemnified Party’s choice of counsel or other representative shall not be unreasonably withheld or delayed.

  

	 	c)	 No final settlement or compromise of any such Demand may be made by a Party without the prior express written
consent or approval of the other Party. 

  
 [Page 20 of 25] 

 11.4 Notice 

A Party having reason to believe that it may be entitled to indemnification shall give reasonably prompt written notice to the other Party from
whom indemnification may be sought, specifying in reasonable detail the nature and basis of any Demand or other matter (including actual and direct damages incurred (other than as a result of a third party claim) which may give rise to such
indemnification, but such notice shall not be a condition of such indemnification. The failure of the Indemnified Party to provide such notice shall not relieve the Indemnifying Party of its indemnification obligations under this Agreement, unless
the delay or failure to provide such notice prejudices an Indemnifying Party in a manner that demonstrably results in actual and direct damages to such Indemnifying Party, in which event such Indemnifying Party shall be relieved of such obligations
but only to the extent such actual and direct damages can be proved. 
 12.    REPRESENTATIONS AND WARRANTIES 

Each Party represents and warrants that they have and shall maintain throughout the Term and any Renewal Term all necessary licenses required
to perform its obligations, is in good standing to perform its obligations, and will perform its obligations in material compliance with all applicable Laws. 

13.    MISCELLANEOUS 

13.1 Dispute Resolution; Arbitration 

Any dispute between the Parties arising out of or relating to this Agreement, either during or after the Term, including the question as to
whether a particular matter is arbitratable, shall be solely and finally resolved by expedited binding arbitration conducted in Florida in accordance with the American Arbitration Association commercial arbitration rules (the “AAA
Rules”). The Party requesting arbitration shall serve upon the other Party a written demand for arbitration stating the substance of the controversy. A panel of three (3) arbitrators, experienced in business transactions similar to
transactions covered by this Agreement and selected in accordance with established AAA procedures, shall conduct the arbitration. The Parties agree to make their respective records available to each other in the arbitration without recourse to
formal discovery and to make their respective personnel available for testimony in the arbitration. The decision of the arbitrators shall be in writing, shall set forth the basis therefor, and shall be final and binding upon the Parties. The Parties
shall divide equally the administrative charges, arbitrators’ fees, and related expenses of arbitration, but each Party shall pay its own legal fees and expenses incurred in connection with the arbitration, unless the arbitrators as part of
their decision require either Party to pay the fees and expenses of the other. 
 13.2 Remedies at Law 

The Parties agree that remedies at law may be inadequate to remedy any breach of the obligations in this Agreement. Accordingly, the Parties
agree that injunctive relief, including temporary restraining order, preliminary and permanent injunctive relief may be obtained without the posting of a bond by either Party to protect its rights under this Agreement, in addition to any other
remedy that may be available. 

  
 [Page 21 of 25] 

 13.3 Contracts, Leases and Purchases 

Except as specifically provided in this Agreement, neither Party shall enter into any agreement in the other Party’s name or that
obligates the other Party without the other Party’s advance written consent. 
 13.4 Assignment 

Except as expressly provided in this Agreement, neither this Agreement nor any right under this Agreement is assignable in whole or in part by
either Party without the prior written consent of the other Party, which shall not be unreasonably withheld, and any attempted assignment without such consent shall be null and void except that either Party may assign its rights and obligations
under this Agreement to its parent, a subsidiary or other Affiliate, or any successor entity resulting from a Change of Control of that Party. 

13.5 Complete Agreement 

This Agreement including all the Exhibits which are hereby incorporated by reference into this Agreement constitutes the complete and
integrated understanding of the Parties with respect to the subject matter of and supersedes all prior understandings and agreements, whether written or oral, with respect to the same subject matter. 

13.6 Amendment 
 This
Agreement may only be amended by a written agreement duly signed by persons authorized to sign agreements on behalf of each of the respective Parties. 

13.7 Amendment to Comply with Law; Severability 

To the extent this Agreement or any provision of this Agreement is deemed to be in violation of applicable Law, then the Parties agree to
negotiate in good faith to amend the Agreement to the extent possible consistent with its purposes, to conform to Law. If any provision of this Agreement shall be held to be invalid, illegal or unenforceable for any reason, the validity, legality
and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
 13.8 Governing Law 

This Agreement, and any and all tort claims that may arise in connection with the performance by either Party of its obligations under this
Agreement shall be governed by the laws of the state of North Carolina, without regard for that body of law known as conflicts of laws. 

13.9 Non-Waivers 

No express or implied waiver by either Party of any Event of Default hereunder shall in any way be, or be construed as, a waiver of any future
or subsequent Event of Default. 

  
 [Page 22 of 25] 

 13.10 Tax-Exempt Status 

Notwithstanding any other provision of this Agreement, CORD:USE acknowledges that with respect to this Agreement, Duke shall not be required to
engage in any activity that compromises the tax-exempt status of Duke or that presents a reasonable likelihood of imposition of intermediate sanctions as described in Section 4958 of the Code. 

13.11 Independent Contractors 

Duke and CORD:USE are, and shall remain independent contractors, each responsible only for its own acts and/or omissions. Nothing in this
Agreement shall be construed to constitute Duke and CORD:USE as partners, joint venturers, agents or anything other than independent contractors. 

13.12 Notices 
 All
notices, demands, requests or other communications which may be or are required to be given, served or sent by any Party to any other Party pursuant to this Agreement shall be in writing and shall be hand delivered (including delivery by courier),
sent by Federal Express or by other recognized overnight delivery service, mailed by first-class, registered or certified mail, return receipt requested, postage prepaid, or sent by telegram, or facsimile transmission with receipt confirmed,
addressed as follows: 
 If to CORD:USE: 

CORD:USE Cord Blood Bank, Inc. 

1991 Summit Park Drive 
 Suite
2000 
 Orlando, FL 32810 

ATTN: Edward Guindi, M.D. 
 Tel: 407/667-3000 
 Fax: 407/667-3003 

With a copy (which shall not constitute notice) to: 

Greenburg Traurig, P.A. 
 450 S.
Orange Avenue 
 Suite 650 

Orlando FL 32801 
 ATTN: Andrew
Finkelstein 
 Tel: 407/317-8577 

Fax: 407420-5909 

  
 [Page 23 of 25]

 If to Duke: 

Duke University School of Medicine 

130 Davison Building 
 Durham, NC
27710 
 Attn: J. Scott Gibson 

Tel: 919-684-0190 

Fax: 919-684-0208 

With a copy (which shall not constitute notice) to: 

Ann Bradley- 
 Duke University

 Office of Counsel 
 310
Blackwell Street, 4th Floor 
 Box 104124 

Durham, NC 27710 
 Tel: 919-684-3955 
 Fax: 919-684-8725 
 Each Party may designate by notice in writing a new address to which any notice,
demand, request or communication may thereafter be so given; served, or sent. Each notice, demand, request, or communication which shall be mailed, delivered, or transmitted in the manner described above shall be deemed sufficiently given, served,
sent, or received for all purposes at such time as it is delivered to addressee (with the return receipt, the delivery receipt, the affidavit of messenger, or (with respect to facsimile) the answer back being deemed conclusive, but not exclusive,
evidence of such delivery) or at such time as delivery is refused by the addressee upon presentation. 
 13.13 Survival 

Neither expiration nor termination of this Agreement shall terminate those obligations and rights of the Parties pursuant to provisions of this
Agreement which by their express terms are intended to survive and such provisions shall survive the expiration or termination of this Agreement. Without limiting the foregoing, the respective rights and obligations of the Parties under
Section 4 (Access to Records and Data), Section 6 (Intellectual Property Rights), Section 7 (Confidentiality and Non-Disclosure),
Section 9.5 (Effect of Termination), Section 11 (Indemnification), and Section 13 (Miscellaneous) shall survive the expiration or termination of this Agreement regardless
of when such termination becomes effective. 
 13.14 Binding Effect; Limitation on Benefit 

This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors, heirs, executors,
administrators, legal representatives and permitted assigns. It is the explicit intention of the Parties that no person or entity other than the Parties is or shall be entitled to bring any action to enforce any provision of this Agreement against
any of the Parties, and the covenants, undertakings and agreements set forth in this Agreement shall be solely for the benefit of, and shall be enforceable only by, the Parties or their respective successors, heirs, executors, administrators, legal
representatives and permitted assigns. 

  
 [Page 24 of 25] 

 13.15 Headings 

Section headings contained in this Agreement are inserted for convenience of reference only, shall not be deemed to be a part of this Agreement
for any purpose, and shall not in any way define or affect the meaning, construction or scope of any of its provisions. 
 13.16
Counterparts; Facsimile Signatures 
 This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same document. Facsimile signatures shall have the same effect as original signatures. 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and delivered in their name and on their behalf as of the date first
set forth above. 
  

					
	“CORD:USE”	  		  	“DUKE”
			
	CORD:USE BLOOD BANK, INC.	  		  	DUKE UNIVERSITY
			
	By: /s/ Michael T. Ernst                	  		  	By: /s/ J. Scott Gibson                
	Name: Michael T. Ernst	  		  	Name: J. Scott Gibson
	Title: Executive Vice President and	  		  	Title: Executive Vice Dean for
	Chief Financial Officer	  		  	Administration School of Medicine
	Date: July 28, 2017	  		  	Date: July 27, 2017

  
 [Page 25 of 25]Document

Exhibit 10.1

ADVISOR AGREEMENT

    This Advisor Agreement (“Agreement”) is made and entered into by and between MRC Energy Company (“Matador”) and Matthew V. Hairford, as an advisor (“Advisor”), to be effective on the date signed by last party to sign below.

WITNESSETH:

    WHEREAS, Matador desires to retain Advisor to provide services as a special advisor to the Board of Directors and Chairman of the Board and Chief Executive Officer of Matador Resources Company (the “Company”) for the period and on the basis set forth herein, and Advisor desires to be so retained by Matador;

    NOW, THEREFORE, in consideration of the mutual premises and covenants herein contained, the parties hereto agree as follows:

1.Matador hereby retains Advisor as a special advisor to the Board of Directors and Chairman of the Board and Chief Executive Officer of the Company for the time and on the basis set forth herein.

2.The term of this Agreement shall commence simultaneously with Advisor’s retirement from his position as President of the Company on March 31, 2022 and shall continue through the close of business on December 31, 2023 (the “Primary Term”), unless earlier terminated in accordance with Paragraph 11; provided, however, subject to Paragraph 11, upon its expiration, the Primary Term shall be extended automatically month-to-month (any such extension together with the Primary Term, the “Term”).

3.Throughout the Term, Advisor hereby accepts and agrees to devote Advisor’s best efforts in the interests of Matador and the Company to the performance of the Services (as defined below).  Such Services shall be performed (i) in the Company’s corporate office in Dallas, Texas, (ii) on the Company’s oil and natural gas properties in West Texas and Southeast New Mexico and (iii) at such other locations as may reasonably be requested by the Chairman of the Board.  During the Term, Advisor agrees not to accept employment with or provide services for any other party if the possibility exists that there may be a conflict of interest between Matador or the Company and such party.  In such case, Advisor agrees to advise Matador in writing in advance of any potential opportunities for employment with, or the provision of services to, any such party, and may not accept such employment or provide any services to such party until Advisor has received confirmation in writing from Matador that in Matador’s sole judgment no conflict of interest exists.

4.Advisor shall report to the Chairman of the Board, or his successor, and/or such other personnel of Matador or its parent or affiliated companies as designated from time to time by the Chairman of the Board, or by any of the executive officers of the Company.  Advisor shall meet periodically with the Chairman of the Board to discuss specific services to be performed by Advisor.  

5.This Agreement and Advisor’s services hereunder shall include but are not limited to involvement with the following, as requested by the Board of Directors and/or the Chairman of the Board (the “Services”), during the Term:

a.training and transitioning of responsibility to his successor(s) as reasonably requested by the Chairman of the Board; 
b.consulting with respect to Matador’s drilling, completion and production operations and financial results; 
c.assisting with respect to San Mateo Midstream, LLC’s (“San Mateo”) operations and financial results; 
d.consulting on San Mateo projects, including serving as San Mateo’s representative on certain outside transactions with other parties; 
e.participating in relationships with parties involved in the operations of Matador or San Mateo; 
f.consulting, as needed, on certain legal proceedings and regulatory matters affecting Matador’s or San Mateo’s operations; 
g.consulting on evaluation and development of personnel; 
h.advising the Board of Directors and the Executive Committee on acquisitions and financial matters; and 
i.participating in such other matters as may be determined by the Chairman of the Board.  

6.As compensation for the Services, Matador agrees to pay Advisor a retainer in the amount of $250,000 per year ($20,833 per month).  Such amount will be paid monthly in arrears. In addition, as Services are rendered during the Term, Advisor’s outstanding equity awards granted under the Company’s long-term incentive plans shall continue to vest in accordance with the terms and conditions of the applicable award agreements.  Matador agrees to reimburse Advisor for all reasonable travel expenses incurred in accordance with Matador’s policies then in effect, which shall be payable by Matador, in arrears.  However, Advisor shall be responsible for daily travel expenses to and from Matador’s offices, meals and incidental expenses.  Advisor shall be responsible for the payment of all taxes associated with the amounts received pursuant to this Agreement. 

7.During the Term, Matador may disclose to Advisor information which Matador considers confidential and proprietary.  In addition, Matador considers Advisor’s efforts and Services hereunder, and the work product and results thereof, to be confidential and proprietary information. Advisor agrees not to publish or disclose any such information to others without the prior written consent of Matador.  In the event that Advisor receives a request or is required (by deposition, interrogatory, request for documents, subpoena, civil investigative demand or similar process) to disclose all or any part of confidential and proprietary information received by Advisor, Advisor agrees to immediately notify Matador in writing of any such request or requirement so that Matador may seek an appropriate protective order, or waive compliance with the provisions hereof.  In the event no such protective order is granted and no such waiver is made by Matador, Advisor may disclose only that portion of the confidential information which Advisor is advised by counsel is legally required to be disclosed, and shall exercise Advisor’s reasonable efforts to obtain assurance that confidential treatment will be accorded such confidential information and Advisor shall not be liable for such disclosure unless such disclosure was caused by or resulted from a previous disclosure by Advisor not permitted by this Agreement.  As to the above confidential disclosure to Advisor by Matador and Advisor’s efforts and Services hereunder, the obligation of confidence shall extend from the termination of this Agreement but shall not apply to (a) information which Advisor can show by documents was 
2

already in Advisor’s possession prior to Matador’s disclosure thereof, (b) information that is or becomes known to the general public through no act of Advisor or (c) information which Advisor receives from a third party having the lawful right to disclose such information without breach of any obligation of confidentiality.  Advisor shall not employ others to assist with the provision of Services covered by this Agreement.  Upon termination of this Agreement, Advisor shall surrender to Matador all of Advisor’s work product and all data and information obtained by, utilized by or provided to Advisor in furtherance of this Agreement and Advisor shall not retain any such work product, information or data, or any copies thereof.  Advisor (i) is aware that United States securities laws prohibit any person who has material, nonpublic information about a public company from purchasing or selling securities of that company, or from communicating that information to any other person under circumstances where it is reasonably foreseeable that such person is likely to purchase or sell those securities, (ii) is familiar with the Securities Exchange Act of 1934 (the “Exchange Act”), and (iii) shall not use, nor cause any third party to use, any information in contravention of the Exchange Act.  Advisor shall be subject to the Company’s Insider Trading Policy.  Advisor is hereby notified in accordance with the Defend Trade Secrets Act of 2016 that Advisor will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If Advisor files a lawsuit for retaliation against Matador or its parents or subsidiaries for reporting a suspected violation of law, Advisor may disclose Matador’s trade secrets to Advisor’s attorney and use the trade secret information in the court proceeding if Advisor files any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant to court order.

8.Notwithstanding anything to the contrary, Advisor agrees that, during the Term and for a period of two (2) years from the date of termination of this Agreement, except on behalf of the Company or Matador, Advisor will not compete with the Company either for the services of any employee or engage in any effort to acquire any interest, directly or indirectly, or conduct or have conducted on Advisor’s behalf, or participate in any leasing, geological, geophysical, drilling or other exploration activity or otherwise compete with Matador, or cause or consult with any third party to do any of such activities or otherwise compete, as to the lands covered by any project(s) and matters which Advisor worked on or was exposed to as a consequence of the Services performed under this Agreement or Advisor’s prior employment with Matador, without the express written consent of Matador, which shall not be unreasonably withheld.

9. Advisor agrees to protect and hold the Company and Matador free and harmless against any liability, damage, loss, expense, claim, action or proceeding (a “Claim”) arising in any way out of, in connection with, or resulting from (a) Advisor’s breach of any representation, warranty or obligation under this Agreement or (b) any Claim for bodily injury or death of any person or damage to real or tangible personal property resulting from Advisor’s acts or omissions.  Advisor specifically waives for himself and Advisor’s agents, heirs and successors any Claim for any injury or accidental death rising out of the performance of the Services.

10.During the Term, Advisor will be an independent contractor and Advisor shall not be an employee of Matador or of any of its affiliates, and Advisor will not represent himself as 
3

an employee of Matador or any of its affiliates to any party or parties.  Advisor shall therefore render the Services on a consultancy basis as a professional, without any bond of employment.  Except with regard to COBRA continuation coverage rights in respect of his prior period of employment, the parties confirm and assent that Advisor shall not be eligible for any of Matador’s employee benefits.  Advisor shall provide all tools and equipment necessary to perform the Services hereunder except that Matador may offer to provide certain equipment, software and/or tools for projects it assigns to Advisor and Advisor may elect at Advisor’s sole discretion to utilize the equipment, software and/or tools for the performance of Services.  The parties confirm and assent that Advisor has the right of control on how Services provided hereunder are completed.  Advisor shall carry such insurance as Advisor deems necessary or desirable and Matador shall not be liable to Advisor for the premiums on any such insurance policies issued to Advisor on Advisor’s behalf.  Matador shall not be required to carry for Advisor’s benefit any worker’s compensation or industrial or occupational disease insurance.  Likewise, it is not the intention of the parties hereto to create, expressly or impliedly, a partnership, association or joint venture, and any such partnership, association or joint venture status is hereby expressly denied.  Upon reasonable prior written notice, Matador or its designated agents shall be permitted access to all books and records of Advisor reasonably related to the payments made hereunder and to the performance by Advisor of the Services hereunder, including for the purpose of auditing such books and records, all at the expense of Matador.

11.This Agreement may be terminated by Matador without notice or by Advisor at any time with not less than fifteen (15) days prior written notice.  In the event that Matador terminates this Agreement, Matador shall have no further obligation to pay Advisor hereunder except for actual hours of Services completed by Advisor as of termination by Matador or continue to vest Advisor’s outstanding equity awards.  If Advisor terminates this Agreement, Advisor shall be entitled to all compensation for actual hours of Services completed by Advisor as of termination by Advisor. Neither termination nor completion of this Agreement referred to above shall affect Paragraphs 7, 8, 9 and 10, which provisions shall survive the termination of this Agreement and remain operative and in full force and effect.  

12.Advisor specifically confirms and assents that, as of the beginning of the Term, except with respect to any agreement executed by Advisor in connection with his prior employment with Matador or its affiliates, Advisor is not governed by any non-compete, confidentiality or other agreement or any other circumstance that would in any way restrict, hamper or interfere with Advisor’s ability to provide the Services.  Furthermore, Advisor agrees not to provide to Matador or bring onto its premises any confidential information of a previous employer or other company.

13.Except as otherwise agreed in writing by the parties hereto, all amounts paid to Advisor shall be paid in legal tender of the United States, and shall be by check or wire transfer.

14.This Agreement as to Advisor is personal and may not be assigned or otherwise transferred by Advisor. Matador, however, shall have the right to assign this Agreement to any of its affiliates or successors. This Agreement may not be amended except by written instrument signed by both parties, and no waiver shall be enforceable against any party unless evidenced by a written instrument signed by the party against which enforcement is sought.

4

15.This Agreement shall be construed under and interpreted in accordance with the laws of the State of Texas, excluding laws, rules and principles that otherwise require reference to the laws of another jurisdiction, and venue shall be in Dallas County, Texas.  Any dispute arising out of or relating to this Agreement, including any question relating to its existence, validity or termination, which cannot be amicably resolved by the parties, within 30 days after either party has notified the other party in writing of the existence of such dispute, shall be settled before three arbitrators, one to be appointed by each party and the two so appointed shall appoint the third arbitrator, in accordance with the Commercial Arbitration Rules of the American Arbitration Association, arbitration to be held in Dallas, Texas, U.S.A.; and judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof, the arbitration being final, binding and without right of appeal. A dispute may be submitted to arbitration by either party after the 30-day period mentioned above by notice in writing to the other party.
 
16.Failure of either party hereto to insist upon or require strict compliance with any provision hereof shall not be considered a waiver of such provision or modification of this Agreement unless so specified in writing. The provisions of this Agreement are severable and the invalidity or unenforceability of one or more of the provisions herein shall not have any effect on the validity or enforceability of any other provision. This Agreement may be executed in counterparts, all of which, taken together, shall constitute one and the same original document.

17.Advisor represents that Advisor is either a U.S. Citizen or has the legal right under the laws of the U.S.A. to enter into this Agreement and to provide the Services hereunder, and that Advisor will immediately advise Matador in the event Advisor’s legal status should change.

5

    IN WITNESS WHEREOF, Matador has caused this Agreement to be executed on its behalf by its duly authorized corporate officer and Advisor has hereunto set Advisor’s hand as of the date set forth underneath each respective signature below.

Signature and address for Notice:    MRC ENERGY COMPANY
Address:                One Lincoln Centre
                    5400 LBJ Freeway, Suite 1500
                    Dallas, Texas 75240

                    By: /s/ Joseph Wm. Foran                                                  
            .            Joseph Wm. Foran
                        Chairman of the Board and Chief Executive Officer
        
                    Date: March 31, 2022                                                        

Signature and address for Notice:    Matthew V. Hairford
Address:                _____________________
                    _____________________

                    /s/ Matthew V. Hairford                                                    
                    Matthew V. Hairford

    Date: March 31, 2022                                                        

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]